Is Novo Nordisk Stock a Buy?

For years, Denmark-based Novo Nordisk (NYSE: NVO) was a fairly traditional develop-and-market pharmaceutical company that escaped notice by many investors. Though listed on American stock exchanges, it didn't distinguish itself much in the vast sea that is the domestic biotech and pharmaceutical sectors.This changed dramatically in 2021 when the company's Wegovy won U.S. Food and Drug Administration (FDA) approval for weight loss. Obesity is a problem in the United States and elsewhere, and Wegovy offers a solution. But popularity breeds competition, and the drug isn't the only weight-loss player in the game now.So, should you still consider buying shares of this drugmaker? Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool